Graf Acquisition Corp. IV (GFOR) to Combine with NKGen Biotech in $160M Deal
Graf Acquisition Corp. IV (NYSE:GFOR) has entered into a definitive agreement to combine with clinical-stage biotech company NKGen at an enterprise value of $160 million. Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditionsRead More
To access this post, you must purchase 1 - User: Monthly Plan.